Kevin Feeley Sells 388 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 388 shares of the company’s stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $113.09, for a total transaction of $43,878.92. Following the transaction, the chief financial officer now owns 3,337 shares of the company’s stock, valued at approximately $377,381.33. This represents a 10.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, April 9th, Kevin Feeley sold 15,516 shares of GeneDx stock. The stock was sold at an average price of $92.18, for a total transaction of $1,430,264.88.
• On Wednesday, March 26th, Kevin Feeley sold 8,746 shares of GeneDx stock. The stock was sold at an average price of $95.61, for a total value of $836,205.06.
• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $362,565.79.
• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The shares were sold at an average price of $90.05, for a total value of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84.

GeneDx Stock Performance

NASDAQ:WGS opened at $67.23 on Friday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a twelve month low of $18.80 and a twelve month high of $117.75. The company has a fifty day moving average of $94.30 and a 200-day moving average of $82.57. The firm has a market capitalization of $1.89 billion, a P/E ratio of -34.30 and a beta of 1.93.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.17. The firm had revenue of $87.12 million for the quarter, compared to analyst estimates of $79.90 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on WGS. Wells Fargo & Company dropped their price target on shares of GeneDx from $105.00 to $78.00 and set an “equal weight” rating for the company in a research note on Thursday. TD Securities cut their target price on GeneDx from $135.00 to $110.00 and set a “buy” rating on the stock in a report on Thursday. The Goldman Sachs Group upped their price target on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. Finally, TD Cowen boosted their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $78.14.

Institutional Investors Weigh In On GeneDx

A number of hedge funds have recently added to or reduced their stakes in the company. Barclays PLC lifted its holdings in shares of GeneDx by 346.3% in the 3rd quarter. Barclays PLC now owns 18,921 shares of the company’s stock worth $803,000 after purchasing an additional 14,681 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of GeneDx during the third quarter worth about $301,000. Prudential Financial Inc. bought a new position in GeneDx in the 4th quarter valued at about $7,938,000. JPMorgan Chase & Co. boosted its stake in GeneDx by 617.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 52,161 shares of the company’s stock valued at $2,214,000 after purchasing an additional 44,889 shares during the last quarter. Finally, Principal Financial Group Inc. bought a new stake in GeneDx during the 3rd quarter worth approximately $604,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.